These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10770747)

  • 1. Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2000 May; 44(5):1168-73. PubMed ID: 10770747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.
    Vouillamoz J; Entenza JM; Féger C; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1789-95. PubMed ID: 10858332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.
    Fantin B; Leclercq R; Merlé Y; Saint-Julien L; Veyrat C; Duval J; Carbon C
    Antimicrob Agents Chemother; 1995 Feb; 39(2):400-5. PubMed ID: 7726505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
    Entenza JM; Drugeon H; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study.
    Batard E; Jacqueline C; Boutoille D; Hamel A; Drugeon HB; Asseray N; Leclercq R; Caillon J; Potel G; Bugnon D
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2174-8. PubMed ID: 12069971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.
    Pavie J; Lefort A; Zarrouk V; Chau F; Garry L; Leclercq R; Fantin B
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3061-4. PubMed ID: 12183272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.
    Fantin B; Leclercq R; Garry L; Carbon C
    Antimicrob Agents Chemother; 1997 May; 41(5):931-5. PubMed ID: 9145847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Chambers HF
    J Antimicrob Chemother; 1992 Jul; 30 Suppl A():117-22. PubMed ID: 1399943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis.
    Berthaud N; Huet Y; Diallo N; Desnottes JF
    J Antimicrob Chemother; 1997 May; 39 Suppl A():93-8. PubMed ID: 9511071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of quinupristin-dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection.
    Yanagihara K; Okada M; Fukuda Y; Imamura Y; Kaneko Y; Ohno H; Higashiyama Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
    Chemotherapy; 2004 Nov; 50(5):260-4. PubMed ID: 15528893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci.
    Auckenthaler R; Courvalin P; Féger C; Roche G;
    Clin Microbiol Infect; 2000 Nov; 6(11):608-12. PubMed ID: 11168064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus.
    Giacometti A; Cirioni O; Ghiselli R; Orlando F; Mocchegiani F; Silvestri C; Licci A; De Fusco M; Provinciali M; Saba V; Scalise G
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4042-5. PubMed ID: 16189078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2662-5. PubMed ID: 11502549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.
    Malbruny B; Canu A; Bozdogan B; Fantin B; Zarrouk V; Dutka-Malen S; Feger C; Leclercq R
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2200-7. PubMed ID: 12069975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin.
    Singh KV; Weinstock GM; Murray BE
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1845-50. PubMed ID: 12019099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Rybak MJ; Houlihan HH; Mercier RC; Kaatz GW
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1359-63. PubMed ID: 9174199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2880-2. PubMed ID: 10991879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.